We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care ...

"PROJECT WATSON" and "BAUSCH + LOMB" are printed on the label. One of two recalled lot numbers, A09050 and A10055, is printed on the bottom of the container.

Bausch + Lomb Corporation Registered Shs Reg S News More News Historical Prices for Bausch + Lomb Corporation Registered Shs Reg S Bausch + Lomb Corporation Registered Shs Reg S Analyst Data ...

Bausch + Lomb Corporation (BLCO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on May 17. Analyst Larry Biegelsen from Wells Fargo maintained a Buy ...

Nasha is a Managing Editor for CNET, overseeing our sleep and wellness verticals. She is a nutrition, mental health, fitness and sleep science enthusiast. Her passion for mindful and holistic ...

GAAP Net Loss Attributable to Bausch + Lomb Corporation of $167 Million Adjusted EBITDA (non-GAAP) 1 of $180 Million Revenue Grew 18% as Reported and 20% on a Constant Currency 1 Basis Compared to ...

Bausch + Lomb (NYSE:BLCO) said a study for its new nutritional supplement for dry eyes met its primary endpoints of change in tear production and participant reports of dry eye symptoms.

Image Source: Zacks Investment Research The company reports revenues through five segments — Salix, International, Diversified Products, Solta Medical and Bausch + Lomb. Salix revenues totaled $ ...

Today's IPO for Bausch + Lomb Corporation (BLCO) opened for trading at $18.50 after pricing 35,000,000 common shares at a public offering price of $18.00 per share, below the... Bausch + Lomb ...